Undeterred by Vertex's plans, biotech Dyne enters Duchenne drug fray

The field of biotechs developing treatments for Duchenne muscular dystrophy became more crowded this week, with biotech startup Dyne setting its sights on the muscle-wasting rare disease.

Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 13, 2019 Category: Pharmaceuticals Authors: Allison DeAngelis Source Type: news